Jennifer Tousignant - 12 Feb 2024 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Legal Officer
Signature
/s/ Jennifer Tousignant
Issuer symbol
VRDN
Transactions as of
12 Feb 2024
Net transactions value
$0
Form type
4
Filing time
14 Feb 2024, 16:05:18 UTC
Next filing
04 Mar 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Award $0 +290,000 $0.000000 290,000 12 Feb 2024 Common Stock 290,000 $19.68 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% on February 12, 2025 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date.